Teva Pharmaceutical Industries (TEVA) Cash & Current Investments: 2009-2024
Historic Cash & Current Investments for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $3.3 billion.
- Teva Pharmaceutical Industries' Cash & Current Investments fell 33.62% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 billion, marking a year-over-year decrease of 20.63%. This contributed to the annual value of $3.3 billion for FY2024, which is 2.29% up from last year.
- Latest data reveals that Teva Pharmaceutical Industries reported Cash & Current Investments of $3.3 billion as of FY2024, which was up 2.29% from $3.2 billion recorded in FY2023.
- Over the past 5 years, Teva Pharmaceutical Industries' Cash & Current Investments peaked at $3.3 billion during FY2024, and registered a low of $2.2 billion during FY2021.
- For the 3-year period, Teva Pharmaceutical Industries' Cash & Current Investments averaged around $3.1 billion, with its median value being $3.2 billion (2023).
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Cash & Current Investments dropped by 0.55% in 2021, and later grew by 29.38% in 2022.
- Over the past 5 years, Teva Pharmaceutical Industries' Cash & Current Investments (Yearly) stood at $2.2 billion in 2020, then fell by 0.55% to $2.2 billion in 2021, then rose by 29.38% to $2.8 billion in 2022, then increased by 15.17% to $3.2 billion in 2023, then increased by 2.29% to $3.3 billion in 2024.